Loading organizations...
§ Private Profile · Boston, MA, USA
Biopharma company developing biosimilar monoclonal antibodies & therapeutic proteins for autoimmune & rare diseases.
Epirus Biopharmaceuticals was a Boston, Massachusetts-based biotechnology company that developed biosimilar monoclonal antibodies and therapeutic proteins targeting autoimmune conditions and rare diseases. The enterprise pursued a global commercialization strategy through regional partnerships, advancing a clinical pipeline that featured biosimilar equivalents to major biologic drugs like Remicade, Soliris, and Actemra. To fund these development efforts, Epirus secured substantial venture capital, highlighted by a $36 million Series B financing round in 2013 led by Livzon Mabpharm, alongside institutional backers TPG Biotech, 5AM Ventures, and Montreux Equity Partners. Following an all-stock merger with Zalicus, the corporate entity scaled to a peak headcount of 73 employees by March 2015, though subsequent financial constraints forced a 40 percent workforce reduction and a strategic pipeline pivot. Epirus Biopharmaceuticals was founded in 2011 by founding chief executive officer Amit Munshi.
Epirus Biopharmaceuticals has raised $36.0M across 1 funding round.
Epirus Biopharmaceuticals has raised $36.0M in total across 1 funding round.
Epirus Biopharmaceuticals has raised $36.0M across 1 funding round. Most recently, it raised $36.0M Series B in April 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 16, 2014 | $36M Series B | Daotian FU | 5AM Ventures, Adage Capital Management, Gibralt US, Greenwoods Investment, Monashee Investment Management, Montreux Equity Partners, Mousse Partners, TPG Biotech | Announced |
Epirus Biopharmaceuticals has raised $36.0M in total across 1 funding round.
Epirus Biopharmaceuticals's investors include Daotian Fu, 5AM Ventures, Adage Capital Management, Gibralt US, Greenwoods Investment, Monashee Investment Management, Montreux Equity Partners, Mousse Partners, TPG Biotech.